Bank stocks have rebounded in recent months as strong results from lenders' retail businesses helped drive firms to record profits.Financeread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
Johnson & Johnson reports second-quarter earnings Tuesday before market open.Health and Scienceread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Analysts polled by Refinitiv are expecting earnings of $4.89 per share and revenue of $88.828 billion when Goldman Sachs reports second-quarter earnings Tuesday.Financeread more
Early Facebook investor and Trump supporter Peter Thiel weighed in on the Democrats taking on the president in 2020, saying he was "most scared' by Elizabeth Warren.Politicsread more
Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Treasury Secretary Steven Mnuchin is raising red flags ahead of Facebook's proposed cryptocurrency launch.Marketsread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
Beto O'Rourke's campaign for the 2020 election raised just $3.6 million in the second quarter of this year, putting him in the lower tier of candidates who have struggled to...2020 Electionsread more
Biopharmaceutical company Amarin is "just getting started" in treating cardiovascular patients, CEO John Thero told CNBC on Wednesday.
Shares have surged more than 660 percent in the last six months on the hopes the company's omega-3 capsule, Vascepa, will be approved for additional uses. It is already being used to treat patients with very high triglycerides — but a clinical trial has also shown it reduced the risk of serious cardiovascular events in statin-treated adults with elevated risk.
"We just doubled the size of our sales force. We will be applying next month to the FDA to get the expanded label," Thero said on "Power Lunch. " "Assuming we get approved there, we'll further expand our sales force. There's tens of millions of patients who can potentially benefit from this therapy."
In its earnings release on Wednesday, Amarin reaffirmed its guidance for 2019. It expects net revenue to grow by more than 50 percent over 2018, to reach $350 million this year. The potential label expansion isn't included in that figure because the company doesn't expect an answer from the FDA until late 2019 or early 2020.
The clinical trial showed Vascepa "could help improve heart health even more" for those patients already on traditional statins, Thero said. Statins lower cardiovascular risks by 25 percent to 35 percent, he said.
"What we have shown is that in those patients who already have their cholesterol well managed, that we can lower that risk by another 25 percent and lower the risk of death by 20 percent," he said. "So this is sort of a new paradigm in cardiovascular health management."
Thero also stressed that the company wants to keep the drug affordable, pointing out that it is priced at about one-fifth of what recent launches of new products in the cardiovascular market cost. "By making it affordable, more and more patients can use it." For patients with insurance, it should cost about $9 a month, he said.
"We really think we're just getting started. Just like statins took a while — really over more than a decade to grow — but now treat about 40 million patients, there's about an equal number of patients who can potentially benefit from Vascepa."